Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:ATMR

Altimar Acquisition Corp. II (ATMR) Stock Price, News & Analysis

About Altimar Acquisition Corp. II Stock (NYSE:ATMR)

Key Stats

Today's Range
N/A
50-Day Range
$9.35
$10.53
52-Week Range
N/A
Volume
355,800 shs
Average Volume
146,007 shs
Market Capitalization
$454.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Altimar Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded in 2020 and is based in New York, New York.

Receive ATMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimar Acquisition Corp. II and its competitors with MarketBeat's FREE daily newsletter.

ATMR Stock News Headlines

RFAI RF Acquisition Corp II
Ares Acquisition Corporation II (AACT)
No one’s talking about these Trump trades
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Altimar Acquisition Corp. II Class A
PMGM Priveterra Acquisition Corp.
See More Headlines

ATMR Stock Analysis - Frequently Asked Questions

Altimar Acquisition Corp. II (ATMR) raised $24 million in an IPO on Friday, August 5th 2016. The company issued 3,200,000 shares at $7.50 per share. National Securities Corporation served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Altimar Acquisition Corp. II investors own include Atreca (BCEL), Black Diamond Therapeutics (BDTX), Editas Medicine (EDIT), F5 (FFIV), Galileo Acquisition (GLEO), Harpoon Therapeutics (HARP) and LogicBio Therapeutics (LOGC).

Company Calendar

Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Fabricated Structural Metal Products
Sub-Industry
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$454.11 million
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NYSE:ATMR) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners